Wednesday August 12, 2026 4:05 PM ET

RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth

Tuesday August 11, 2026 8:30 AM ET

RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer

Thursday August 6, 2026 8:30 AM ET

RenovoRx Announces First Commercial Clinical Use of RenovoCath® in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors

Tuesday August 4, 2026 8:30 AM ET

RenovoRx to Highlight TAMP™ Platform at JonesTrading Virtual Key Opinion Leader Webinar on the Evolving Pancreatic Cancer Landscape, August 13th

Wednesday July 29, 2026 8:30 AM ET

RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET

Thursday June 11, 2026 8:30 AM ET

RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP™ in Locally Advanced Pancreatic Cancer

Thursday June 4, 2026 8:30 AM ET

RenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rd

Thursday May 28, 2026 8:30 AM ET

RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer

Tuesday May 26, 2026 8:30 AM ET

RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting

Tuesday May 19, 2026 8:30 AM ET

RenovoRx to Present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20th

Thursday May 14, 2026 4:05 PM ET

RenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-Quarter

Wednesday April 29, 2026 8:30 AM ET

RenovoRx to Host First Quarter 2026 Financial Results and Business Highlights Conference Call on May 14th at 4:30 pm ET

Thursday April 23, 2026 8:30 AM ET

RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP™ Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting

Tuesday April 14, 2026 8:30 AM ET

Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx’s TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific Meeting

Wednesday April 8, 2026 8:30 AM ET

RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath® Device for Targeted, Local Drug-Delivery via the Vasa Vasorum

Wednesday April 1, 2026 2:20 PM ET

RenovoRx Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026

Monday March 30, 2026 4:05 PM ET

RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update

Thursday March 26, 2026 8:30 AM ET

RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of Enrollment

Monday March 23, 2026 8:30 AM ET

RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement

Monday March 23, 2026 8:30 AM ET

RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement

Wednesday March 18, 2026 8:35 AM ET

RenovoRx Announces $10 Million at Market Private Placement

Friday February 27, 2026 8:30 AM ET

RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum

Thursday February 26, 2026 8:30 AM ET

RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Radiology Annual Scientific Meeting